Vericiguat for the treatment of heart failure with reduced ejection fraction.
Ahmed K SiddiqiStephen J GreeneMarat FudimRobert J MentzJaved ButlerMuhammad Shahzeb KhanPublished in: Expert review of cardiovascular therapy (2023)
Vericiguat reduces the risk of cardiovascular mortality or HF hospitalizations by an absolute event-rate reduction of 4.2 events per 100 patient-years with a number needed to treat of 24 patients, on a background of guideline-directed medical therapy. Almost 90% of the patients with HFrEF were adherent to the 10 mg dose of vericiguat in the VICTORIA trial with a favorable tolerability and safety profile. Considering the high residual risk that persists in HFrEF, vericiguat has a role to improve outcomes among patients with worsening HFrEF.
Keyphrases
- heart failure
- end stage renal disease
- ejection fraction
- newly diagnosed
- healthcare
- clinical trial
- study protocol
- open label
- prognostic factors
- cardiovascular events
- randomized controlled trial
- case report
- phase ii
- cardiovascular disease
- risk factors
- metabolic syndrome
- patient reported outcomes
- adipose tissue
- weight loss